Adam Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adam Khan has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Matt Vassar
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, United States
11 shared publications- Matt Vassar
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
5 shared publications Will Roberts
Department of Pain Management and Anesthesiology, Baylor Scott & White Medical Center, Temple, TX, United States
5 shared publicationsAaron Relic
Department of Anesthesiology, Oklahoma State University Medical Center, Tulsa, OK, United States
4 shared publicationsBryan Dunford
Department of Anesthesiology, Oklahoma State University Medical Center, Tulsa, Oklahoma, USA
3 shared publicationsMicah Hartwell
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, United States
3 shared publications
Latest Publications
- 26 December 2025
- Published by Elsevier in Oral Oncology
- Vol. 173, 107840
Safety reporting in head and neck squamous cell carcinoma clinical Trials: A comparative analysis of ClinicalTrials.gov data and published research
- 26 December 2025
- Published by Elsevier in Oral Oncology
- Vol. 173, 107840
Safety reporting in head and neck squamous cell carcinoma clinical Trials: A comparative analysis of ClinicalTrials.gov data and published research
- Open Access
- 3 December 2025
- Published by Frontiers Media SA in Frontiers in Pain Research
- Vol. 6, 1704833
Reporting and methodological quality of systematic reviews underpinning clinical practice guidelines for low back pain: a meta-epidemiological study
Background: Low back pain (LBP) is the leading musculoskeletal disorder worldwide and a major cause of disability, health care utilization, and economic burden. Clinical practice guidelines (CPGs) aim to optimize care but depend heavily on systematic reviews (SRs). The reporting and methodological quality of SRs underpinning LBP CPGs remain unclear. Objectives: To conduct a meta-epidemiological assessment of the reporting and methodological quality of SRs cited in LBP CPGs and compare Cochrane vs. non-Cochrane reviews. Methods and design: Cross-sectional meta-epidemiological study. We identified English-language LBP CPGs published between 2017 and 2021 and extracted SRs underpinning therapeutic recommendations. Reporting quality was assessed using PRISMA and methodological quality using AMSTAR-2. Two reviewers performed masked, duplicate extraction with consensus resolution. Between-group comparisons used Wilcoxon rank-sum tests; prespecified subgroup analyses (by intervention domain) and an exploratory multivariable linear regression examined factors associated with PRISMA scores. Results: Eight CPGs cited 90 unique SRs. Mean PRISMA adherence was 83% (SD: 12.2); 39% of SRs met ≥90% of items. Mean AMSTAR-2 adherence was 79.3% (SD: 14.4); 24% were rated overall “high,” while 14% were “low/critically low.” Common deficits included protocol registration, justification of excluded studies, and assessment of small study/publication bias. Cochrane SRs ( n = 22) had higher PRISMA (91% vs. 81%) and AMSTAR-2 (88% vs. 76%) scores than non-Cochrane SRs (both p < 0.001). Interventional technique SRs tended to have slightly lower PRISMA scores than pharmacologic SRs after adjustment, whereas noninvasive non-pharmacologic SRs were similar. In exploratory regression, higher AMSTAR-2 ratings and predominance of randomized trials were associated with higher PRISMA scores. Conclusions: SRs informing LBP CPGs show variable reporting and methodological quality with consistent shortfalls in protocol registration, exclusion justifications, and publication-bias assessment. Cochrane SRs outperformed non-Cochrane SRs yet comprised only a minority of the evidence base. Facilitating uptake of protocol registration, complete PRISMA-aligned reporting, transparent exclusion lists, and routine small-study bias assessment, alongside greater use of methodologically stronger SRs, could strengthen the evidentiary foundation of LBP guidelines.
- 3 December 2025
- Published by Frontiers Media SA in Frontiers in Pain Research
- Vol. 6, 1704833
Open AccessReporting and methodological quality of systematic reviews underpinning clinical practice guidelines for low back pain: a meta-epidemiological study
Background: Low back pain (LBP) is the leading musculoskeletal disorder worldwide and a major cause of disability, health care utilization, and economic burden. Clinical practice guidelines (CPGs) aim to optimize care but depend heavily on systematic reviews (SRs). The reporting and methodological quality of SRs underpinning LBP CPGs remain unclear. Objectives: To conduct a meta-epidemiological assessment of the reporting and methodological quality of SRs cited in LBP CPGs and compare Cochrane vs. non-Cochrane reviews. Methods and design: Cross-sectional meta-epidemiological study. We identified English-language LBP CPGs published between 2017 and 2021 and extracted SRs underpinning therapeutic recommendations. Reporting quality was assessed using PRISMA and methodological quality using AMSTAR-2. Two reviewers performed masked, duplicate extraction with consensus resolution. Between-group comparisons used Wilcoxon rank-sum tests; prespecified subgroup analyses (by intervention domain) and an exploratory multivariable linear regression examined factors associated with PRISMA scores. Results: Eight CPGs cited 90 unique SRs. Mean PRISMA adherence was 83% (SD: 12.2); 39% of SRs met ≥90% of items. Mean AMSTAR-2 adherence was 79.3% (SD: 14.4); 24% were rated overall “high,” while 14% were “low/critically low.” Common deficits included protocol registration, justification of excluded studies, and assessment of small study/publication bias. Cochrane SRs ( n = 22) had higher PRISMA (91% vs. 81%) and AMSTAR-2 (88% vs. 76%) scores than non-Cochrane SRs (both p < 0.001). Interventional technique SRs tended to have slightly lower PRISMA scores than pharmacologic SRs after adjustment, whereas noninvasive non-pharmacologic SRs were similar. In exploratory regression, higher AMSTAR-2 ratings and predominance of randomized trials were associated with higher PRISMA scores. Conclusions: SRs informing LBP CPGs show variable reporting and methodological quality with consistent shortfalls in protocol registration, exclusion justifications, and publication-bias assessment. Cochrane SRs outperformed non-Cochrane SRs yet comprised only a minority of the evidence base. Facilitating uptake of protocol registration, complete PRISMA-aligned reporting, transparent exclusion lists, and routine small-study bias assessment, alongside greater use of methodologically stronger SRs, could strengthen the evidentiary foundation of LBP guidelines.
- Open Access
- 17 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5289-5292
Incomplete harms reporting in systematic reviews of direct oral factor Xa inhibitors
- 17 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5289-5292
Open AccessIncomplete harms reporting in systematic reviews of direct oral factor Xa inhibitors
- Open Access
- 13 October 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (10) , 1221-1228
Clinical utility of randomized controlled trials of regional anesthesia for lower-extremity surgery: a systematic review
Background: Regional anesthesia (RA) is central to multimodal analgesia, yet many supporting randomized controlled trials (RCTs) may lack the rigor needed for evidence-based block selection. Objectives: To evaluate the clinical usefulness and transparency of RCTs investigating RA interventions for lower extremity surgeries, using the van ’t Hooft et al framework. Methods: Embase/MEDLINE were searched for RCTs (2014–2024) examining RA interventions for lower-extremity surgery. Data were extracted in duplicate using clinical-utility and transparency criteria. Analyses included descriptive statistics, linear regression for temporal trends, Pearson correlation, and multivariable regression to identify predictors of usefulness. Results: Among 248 RCTs, patient-centeredness was universal, while feasibility (77.0%) and context placement (77.4%) were common. Pragmatism (2.0%) and value-for-money analyses (0%) were rare. Transparency varied: conflicts of interest were disclosed in 88.7%, pre-registration occurred in 39.9%, public protocols in 10.1%, and raw-data sharing in 1.2%. Transparency improved over time, correlated with clinical-utility scores (r=0.32, p<0.001) and was greater in hospital-funded, self-funded, and higher-impact journals. Limitations: Usefulness scoring involves subjective judgment; non-English trials were excluded; the absence of formal risk of bias analysis limits interpretability of trial quality. Discussions/conclusions: Although transparency is improving, most trials remain insufficiently pragmatic, lack economic evaluation, and rarely share data, limiting real-world applicability. The results of this study suggest that aligning funder, journal, and collaborative expectations around open science and pragmatic design could accelerate the generation of high-utility evidence for perioperative block selection.
- 13 October 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (10) , 1221-1228
Open AccessClinical utility of randomized controlled trials of regional anesthesia for lower-extremity surgery: a systematic review
Background: Regional anesthesia (RA) is central to multimodal analgesia, yet many supporting randomized controlled trials (RCTs) may lack the rigor needed for evidence-based block selection. Objectives: To evaluate the clinical usefulness and transparency of RCTs investigating RA interventions for lower extremity surgeries, using the van ’t Hooft et al framework. Methods: Embase/MEDLINE were searched for RCTs (2014–2024) examining RA interventions for lower-extremity surgery. Data were extracted in duplicate using clinical-utility and transparency criteria. Analyses included descriptive statistics, linear regression for temporal trends, Pearson correlation, and multivariable regression to identify predictors of usefulness. Results: Among 248 RCTs, patient-centeredness was universal, while feasibility (77.0%) and context placement (77.4%) were common. Pragmatism (2.0%) and value-for-money analyses (0%) were rare. Transparency varied: conflicts of interest were disclosed in 88.7%, pre-registration occurred in 39.9%, public protocols in 10.1%, and raw-data sharing in 1.2%. Transparency improved over time, correlated with clinical-utility scores (r=0.32, p<0.001) and was greater in hospital-funded, self-funded, and higher-impact journals. Limitations: Usefulness scoring involves subjective judgment; non-English trials were excluded; the absence of formal risk of bias analysis limits interpretability of trial quality. Discussions/conclusions: Although transparency is improving, most trials remain insufficiently pragmatic, lack economic evaluation, and rarely share data, limiting real-world applicability. The results of this study suggest that aligning funder, journal, and collaborative expectations around open science and pragmatic design could accelerate the generation of high-utility evidence for perioperative block selection.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 10 (4)
Assessing the Clinical Usefulness and Transparency of Knee Arthroplasty Randomized Controlled Trials (2020-2024): A Systematic Review Using the van't Hooft Framework
Background: Osteoarthritis is the most common joint disorder in the United States, and total knee arthroplasty (TKA) is among the most frequently performed surgeries. Although randomized controlled trials (RCTs) are essential for guiding treatment, their clinical usefulness remains uncertain. This study assessed the utility of TKA RCTs published between 2020 and 2024 using the van't Hooft usefulness framework. Methods: We systematically reviewed RCTs of knee arthroplasty published between 2020 and 2024, identified through MEDLINE and Embase (April 2, 2025). Utility was assessed using the 13-item van't Hooft framework. Linear regression analyzed associations between utility scores and study characteristics, including funding, sample size, and journal impact factor. Results: Of 184 studies, 29.3% met the problem-base criterion. Although 86.4% included patient-centered outcomes, most were secondary. Pragmatism was rare (1.1%). 23.9% were prospectively registered, and 4.9% provided raw data. Transparency and clinical utility were moderately correlated (r = 0.28, p < 0.001). Conclusion: Most RCTs showed internal validity but limited real-world relevance. Narrow eligibility, short follow-up, and poor transparency limit clinical impact. These findings should not be interpreted as a dismissal. Rather, they highlight opportunities to strengthen future trials so that they remain a cornerstone of evidence-based orthopaedics. Level of Evidence: Level II. See Instructions for Authors for a complete description of levels of evidence.
- 1 October 2025
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 10 (4)
Open AccessAssessing the Clinical Usefulness and Transparency of Knee Arthroplasty Randomized Controlled Trials (2020-2024): A Systematic Review Using the van't Hooft Framework
Background: Osteoarthritis is the most common joint disorder in the United States, and total knee arthroplasty (TKA) is among the most frequently performed surgeries. Although randomized controlled trials (RCTs) are essential for guiding treatment, their clinical usefulness remains uncertain. This study assessed the utility of TKA RCTs published between 2020 and 2024 using the van't Hooft usefulness framework. Methods: We systematically reviewed RCTs of knee arthroplasty published between 2020 and 2024, identified through MEDLINE and Embase (April 2, 2025). Utility was assessed using the 13-item van't Hooft framework. Linear regression analyzed associations between utility scores and study characteristics, including funding, sample size, and journal impact factor. Results: Of 184 studies, 29.3% met the problem-base criterion. Although 86.4% included patient-centered outcomes, most were secondary. Pragmatism was rare (1.1%). 23.9% were prospectively registered, and 4.9% provided raw data. Transparency and clinical utility were moderately correlated (r = 0.28, p < 0.001). Conclusion: Most RCTs showed internal validity but limited real-world relevance. Narrow eligibility, short follow-up, and poor transparency limit clinical impact. These findings should not be interpreted as a dismissal. Rather, they highlight opportunities to strengthen future trials so that they remain a cornerstone of evidence-based orthopaedics. Level of Evidence: Level II. See Instructions for Authors for a complete description of levels of evidence.
- Open Access
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 16, 1597019
Reporting of harms in systematic reviews focused on naltrexone: a cross-sectional study
Background: Naltrexone is a pharmacological intervention widely used for alcohol use disorder (AUD), opioid use disorder (OUD), and several off-label conditions. Systematic reviews (SRs) play a critical role in synthesizing data on the efficacy and safety of such interventions to inform clinical guidelines and decision-making. However, adequate reporting of harms in SRs remains inconsistent, limiting the ability to fully assess the safety profile of naltrexone. This study evaluates completeness of harms reporting and methodological quality in SRs focusing on naltrexone.Methods: A comprehensive search of MEDLINE, EMBASE, Epistemonikos, and the Cochrane Database of Systematic Reviews was conducted. The study employed masked, duplicate screening and data extraction. Included SRs were evaluated for completeness of harms reporting using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) harms checklist and other established frameworks. Methodological quality was appraised using the A MeaSurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) tool, and primary study overlap among SRs was assessed through corrected covered area (CCA) analysis.Results: A total of 87 SRs were included in the analysis. Only 1.1% (1/87) utilized severity scales to classify harms, and 4.6% (4/87) defined harms in their methods. Nearly half (48.3%) of SRs failed to address harms as either a primary or secondary outcome. A total of 82.8% (72/87) of SRs were rated as “critically low” quality by AMSTAR-2. Statistical analysis revealed a significant relationship between “critically low” AMSTAR-2 ratings and incomplete harms reporting (p = 0.0486). Additionally, four SR pairs demonstrated “high” overlap (>50%) of primary studies, accompanied by inconsistencies in harms reporting.Conclusion: Our findings underscore the critical need for improved and standardized harms reporting in SRs on naltrexone. Inconsistent and incomplete reporting limits the ability of clinicians to fully assess the safety profile of naltrexone within systematic reviews. Adopting established frameworks such as PRISMA harms extensions and severity scales is imperative to enhance transparency and reliability in SRs. This study advocates for methodological improvements in SRs to support comprehensive safety evaluations and evidence-based prescribing of naltrexone.
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 16, 1597019
Open AccessReporting of harms in systematic reviews focused on naltrexone: a cross-sectional study
Background: Naltrexone is a pharmacological intervention widely used for alcohol use disorder (AUD), opioid use disorder (OUD), and several off-label conditions. Systematic reviews (SRs) play a critical role in synthesizing data on the efficacy and safety of such interventions to inform clinical guidelines and decision-making. However, adequate reporting of harms in SRs remains inconsistent, limiting the ability to fully assess the safety profile of naltrexone. This study evaluates completeness of harms reporting and methodological quality in SRs focusing on naltrexone.Methods: A comprehensive search of MEDLINE, EMBASE, Epistemonikos, and the Cochrane Database of Systematic Reviews was conducted. The study employed masked, duplicate screening and data extraction. Included SRs were evaluated for completeness of harms reporting using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) harms checklist and other established frameworks. Methodological quality was appraised using the A MeaSurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) tool, and primary study overlap among SRs was assessed through corrected covered area (CCA) analysis.Results: A total of 87 SRs were included in the analysis. Only 1.1% (1/87) utilized severity scales to classify harms, and 4.6% (4/87) defined harms in their methods. Nearly half (48.3%) of SRs failed to address harms as either a primary or secondary outcome. A total of 82.8% (72/87) of SRs were rated as “critically low” quality by AMSTAR-2. Statistical analysis revealed a significant relationship between “critically low” AMSTAR-2 ratings and incomplete harms reporting (p = 0.0486). Additionally, four SR pairs demonstrated “high” overlap (>50%) of primary studies, accompanied by inconsistencies in harms reporting.Conclusion: Our findings underscore the critical need for improved and standardized harms reporting in SRs on naltrexone. Inconsistent and incomplete reporting limits the ability of clinicians to fully assess the safety profile of naltrexone within systematic reviews. Adopting established frameworks such as PRISMA harms extensions and severity scales is imperative to enhance transparency and reliability in SRs. This study advocates for methodological improvements in SRs to support comprehensive safety evaluations and evidence-based prescribing of naltrexone.
- Open Access
- 6 August 2025
- Published by Springer Nature in Pain and Therapy
- Vol. 14 (5) , 1531-1546
Adherence to CONSORT-PRO Extension Guidelines for Patient-Reported Outcomes in Randomized Controlled Trials Focused on Peripheral Nerve Blocks: A Meta-epidemiological Study
Introduction Patient-reported outcomes (PROs), such as peri- and postoperative pain scores, capture patient perspectives in regional anesthesia trials. However, whether these outcomes are reported according to established guidelines remains unclear. The CONSORT statement and its PRO extension (CONSORT-PRO) aim to enhance transparency in reporting PROs, yet no study has investigated adherence in peripheral nerve block (PNB) trials. Our meta-epidemiological investigation evaluated how well PNB randomized controlled trials (RCTs) adhere with CONSORT-PRO and explored whether trial characteristics affect reporting quality. Methods We performed a cross-sectional, meta-epidemiological study to determine adherence to CONSORT-PRO reporting guidelines in RCTs. We searched Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and MEDLINE for RCT publications investigating PNBs between 2006 and 2020. RCTs investigating PNBs that incorporated PROs as a primary or secondary outcome were included. All other studies, reviews, or publications without a PRO were excluded. Results In total, 65 RCTs met the inclusion criteria. Mean CONSORT-PRO adherence was 46.80 ± 17.36%, and trials that designated a PRO as the primary endpoint were more adherent than those in which the PRO was secondary (49.27 ± 16.58% versus 38.57 ± 17.92%; P = 0.035). Trials with ≥ 6-month follow-up were 16.24% more adherent than those with ≤ 3-month follow-up (P = 0.006). Studies that used a visual analog scale (VAS) or numeric rating scale (NRS) in combination with other PRO instruments were significantly more adherent than trials using VAS alone (P = 0.028). Conclusions Our meta-epidemiological review reveals substantial nonadherence to CONSORT-PRO guidelines in PNB trials. Although PROs are crucial for capturing patient-centered outcomes, they remain under-reported, especially when treated as secondary endpoints. Using diverse, validated measures beyond VAS/NRS and consistently applying CONSORT-PRO can enhance the quality, transparency, and clinical relevance of future trials. Targeted education for authors, editors, and clinicians—and expanded research on neuraxial techniques—will further strengthen reporting standards and the interpretability of anesthesia evidence.
- 6 August 2025
- Published by Springer Nature in Pain and Therapy
- Vol. 14 (5) , 1531-1546
Open AccessAdherence to CONSORT-PRO Extension Guidelines for Patient-Reported Outcomes in Randomized Controlled Trials Focused on Peripheral Nerve Blocks: A Meta-epidemiological Study
Introduction Patient-reported outcomes (PROs), such as peri- and postoperative pain scores, capture patient perspectives in regional anesthesia trials. However, whether these outcomes are reported according to established guidelines remains unclear. The CONSORT statement and its PRO extension (CONSORT-PRO) aim to enhance transparency in reporting PROs, yet no study has investigated adherence in peripheral nerve block (PNB) trials. Our meta-epidemiological investigation evaluated how well PNB randomized controlled trials (RCTs) adhere with CONSORT-PRO and explored whether trial characteristics affect reporting quality. Methods We performed a cross-sectional, meta-epidemiological study to determine adherence to CONSORT-PRO reporting guidelines in RCTs. We searched Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and MEDLINE for RCT publications investigating PNBs between 2006 and 2020. RCTs investigating PNBs that incorporated PROs as a primary or secondary outcome were included. All other studies, reviews, or publications without a PRO were excluded. Results In total, 65 RCTs met the inclusion criteria. Mean CONSORT-PRO adherence was 46.80 ± 17.36%, and trials that designated a PRO as the primary endpoint were more adherent than those in which the PRO was secondary (49.27 ± 16.58% versus 38.57 ± 17.92%; P = 0.035). Trials with ≥ 6-month follow-up were 16.24% more adherent than those with ≤ 3-month follow-up (P = 0.006). Studies that used a visual analog scale (VAS) or numeric rating scale (NRS) in combination with other PRO instruments were significantly more adherent than trials using VAS alone (P = 0.028). Conclusions Our meta-epidemiological review reveals substantial nonadherence to CONSORT-PRO guidelines in PNB trials. Although PROs are crucial for capturing patient-centered outcomes, they remain under-reported, especially when treated as secondary endpoints. Using diverse, validated measures beyond VAS/NRS and consistently applying CONSORT-PRO can enhance the quality, transparency, and clinical relevance of future trials. Targeted education for authors, editors, and clinicians—and expanded research on neuraxial techniques—will further strengthen reporting standards and the interpretability of anesthesia evidence.
- Open Access
- 13 July 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (11) , 1351-1353
An analysis of patient-reported outcomes among epidural steroid injection clinical trials
Robust reporting of randomized controlled trials (RCTs) lets clinicians judge the credibility of new pain interventions. The CONSORT (Consolidated Standards of Reporting Trials) 2010 statement and its patient-reported outcome (PRO) extension list the details readers need to interpret PRO data.1 2 Epidural steroid injections (ESIs) remain one of the most common spine procedures, yet the adequacy of PRO reporting in ESI RCTs is unknown.3 We evaluated adherence to CONSORT-PRO in these trials.
- 13 July 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (11) , 1351-1353
Open AccessAn analysis of patient-reported outcomes among epidural steroid injection clinical trials
Robust reporting of randomized controlled trials (RCTs) lets clinicians judge the credibility of new pain interventions. The CONSORT (Consolidated Standards of Reporting Trials) 2010 statement and its patient-reported outcome (PRO) extension list the details readers need to interpret PRO data.1 2 Epidural steroid injections (ESIs) remain one of the most common spine procedures, yet the adequacy of PRO reporting in ESI RCTs is unknown.3 We evaluated adherence to CONSORT-PRO in these trials.
- Open Access
- 27 June 2025
- Published by Wiley in Anaesthesia
- Vol. 80 (8) , 1004-1007
Rates of discontinuation and non‐publication of regional anaesthesia clinical trials: a registry‐based cross‐sectional analysis
- 27 June 2025
- Published by Wiley in Anaesthesia
- Vol. 80 (8) , 1004-1007
Open AccessRates of discontinuation and non‐publication of regional anaesthesia clinical trials: a registry‐based cross‐sectional analysis